General Information of Drug Off-Target (DOT) (ID: OTPDZ6XV)

DOT Name Transcription initiation factor TFIID subunit 7-like (TAF7L)
Synonyms Cancer/testis antigen 40; CT40; RNA polymerase II TBP-associated factor subunit Q; TATA box-binding protein-associated factor 50 kDa; Transcription initiation factor TFIID 50 kDa subunit
Gene Name TAF7L
Related Disease
Acute myelogenous leukaemia ( )
Male infertility ( )
High blood pressure ( )
Breast cancer ( )
Breast carcinoma ( )
Breast neoplasm ( )
UniProt ID
TAF7L_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF04658
Sequence
MECPEGQLPISSENDSTPTVSTSEVTSQQEPQILVDRGSETTYESSADIAGDEGTQIPAD
EDTQTDADSSAQAAAQAPENFQEGKDMSESQDEVPDEVENQFILRLPLEHACTVRNLARS
QSVKMKDKLKIDLLPDGRHAVVEVEDVPLAAKLVDLPCVIESLRTLDKKTFYKTADISQM
LVCTADGDIHLSPEEPAASTDPNIVRKKERGREEKCVWKHGITPPLKNVRKKRFRKTQKK
VPDVKEMEKSSFTEYIESPDVENEVKRLLRSDAEAVSTRWEVIAEDGTKEIESQGSIPGF
LISSGMSSHKQGHTSSEYDMLREMFSDSRSNNDDDEDEDDEDEDEDEDEDEDEDKEEEEE
DCSEEYLERQLQAEFIESGQYRANEGTSSIVMEIQKQIEKKEKKLHKIQNKAQRQKDLIM
KVENLTLKNHFQSVLEQLELQEKQKNEKLISLQEQLQRFLKK
Function
Probably functions as a spermatogenesis-specific component of the DNA-binding general transcription factor complex TFIID, a multimeric protein complex that plays a central role in mediating promoter responses to various activators and repressors. May play a role in spermatogenesis.
Tissue Specificity Testis-specific.
KEGG Pathway
Basal transcription factors (hsa03022 )
Reactome Pathway
RNA Polymerase II HIV Promoter Escape (R-HSA-167162 )
Transcription of the HIV genome (R-HSA-167172 )
RNA Polymerase II Pre-transcription Events (R-HSA-674695 )
Regulation of TP53 Activity through Phosphorylation (R-HSA-6804756 )
RNA Polymerase II Promoter Escape (R-HSA-73776 )
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening (R-HSA-73779 )
RNA Polymerase II Transcription Initiation (R-HSA-75953 )
RNA Polymerase II Transcription Initiation And Promoter Clearance (R-HSA-76042 )
HIV Transcription Initiation (R-HSA-167161 )

Molecular Interaction Atlas (MIA) of This DOT

6 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Acute myelogenous leukaemia DISCSPTN Definitive Altered Expression [1]
Male infertility DISY3YZZ Strong Genetic Variation [2]
High blood pressure DISY2OHH moderate Biomarker [3]
Breast cancer DIS7DPX1 Limited Biomarker [4]
Breast carcinoma DIS2UE88 Limited Biomarker [4]
Breast neoplasm DISNGJLM Limited Altered Expression [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the methylation of Transcription initiation factor TFIID subunit 7-like (TAF7L). [5]
------------------------------------------------------------------------------------

References

1 Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern.Med Oncol. 2013 Mar;30(1):368. doi: 10.1007/s12032-012-0368-8. Epub 2013 Jan 6.
2 The role of the testis-specific gene hTAF7L in the aetiology of male infertility.Mol Hum Reprod. 2006 Apr;12(4):263-7. doi: 10.1093/molehr/gal020. Epub 2006 Apr 5.
3 Simultaneous validation of the SunTech CT40 automated blood pressure measurement device by the 1993 British Hypertension Society protocol and the Association for the Advancement of Medical Instrumentation/International Organization for Standardization 81060-2: 2013 standard.Blood Press Monit. 2017 Oct;22(5):298-301. doi: 10.1097/MBP.0000000000000281.
4 Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer.Asian Pac J Cancer Prev. 2015;16(11):4623-8. doi: 10.7314/apjcp.2015.16.11.4623.
5 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.